Stephen P. Hale
Biotech Executive, Company Builder, and Drug Hunter
- Role
- Scientific Advisory Board Member at Totus Medicines
- Location
- Cambridge, MA, US
- LinkedIn followers
- 500 followers
About Stephen P. Hale
Steve has over 25 years of drug discovery experience, most recently as-CEO and Founder of DG Medicines-An operational founder and Global Head of Discovery at Dewpoint Therapeutics-A founder of 2 autoimmune-focused therapeutics companies; A founding member of an E3 Ligase-targeting company in the oncology and neuro-degeneration therapeutic areas-A consultant and entrepreneur advising over 30 emerging and established companiesPrior to consulting and venture creation, Steve was CSO of Ensemble Therapeutics where he built a drug discovery platform supporting 6 major collaborations that raised over $100M in non-dilutive capital. At Ensemble he was responsible for initiating and advancing internal and partnered programs that leveraged DNA-encoded macrocyclic compound collections and a massively parallel screening process. Programs were advanced in oncology, immune modulation, cardiovascular, neurodegeneration, and anti-infectives with an IL17, and IDO antagonists of novel mechanism being acquired and advanced towards the clinic. Before joining Ensemble, Steve was at Praecis Pharmaceuticals where he was co-inventor of a transformative DNA-Encoded Library (DEL) and screening technology that has since become ubiquitous in the industry as the gold-standard for encoded-small-molecule discovery. Programs in oncology were advanced including the approval of Plenaxis for prostate cancer prior to an acquisition by GSK. He joined Praecis from Phylos (Adnexus/BMS), a therapeutics discovery and development company where he was a founding scientist and led the anti-VEGFR2 program (BMS844203) that progressed to phase 2. Dr. Hale was also involved in early work at Genex Inc. on the design and engineering of single-chain antibodies. He received his Ph.D. in biochemistry/chemistry from the University of Maryland, College Park, under Professor John Gerlt and was a National Institutes of Health post-doctoral fellow at the Massachusetts Institute of Technology under the direction of Professor Paul Schimmel.
Experience
Scientific Advisory Board Member
Oct 2021 — Present · Emeryville, CA, US
Education
Massachusetts Institute of Technology
Post Doctoral Fellow, Chemical Biology
1994 — 1997
University of New Hampshire
BS, Biochemistry
1980 — 1984
University of Maryland
Ph.D., Biochemistry/Enzymology
1989 — 1994
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.